Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Depreciation & Amortization (CF): 2013-2024

Historic Depreciation & Amortization (CF) for Akebia Therapeutics (AKBA) over the last 12 years, with Dec 2024 value amounting to $1.5 million.

  • Akebia Therapeutics' Depreciation & Amortization (CF) fell 12.40% to $318,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 15.65%. This contributed to the annual value of $1.5 million for FY2024, which is 7.76% down from last year.
  • Akebia Therapeutics' Depreciation & Amortization (CF) amounted to $1.5 million in FY2024, which was down 7.76% from $1.6 million recorded in FY2023.
  • Akebia Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $2.1 million for FY2020, and its period low was $1.5 million during FY2024.
  • Over the past 3 years, Akebia Therapeutics' median Depreciation & Amortization (CF) value was $1.6 million (recorded in 2023), while the average stood at $1.6 million.
  • In the last 5 years, Akebia Therapeutics' Depreciation & Amortization (CF) fell by 14.17% in 2022 and then grew by 4.17% in 2023.
  • Akebia Therapeutics' Depreciation & Amortization (CF) (MRY) stood at $2.1 million in 2020, then decreased by 7.13% to $1.9 million in 2021, then fell by 14.17% to $1.7 million in 2022, then fell by 4.17% to $1.6 million in 2023, then fell by 7.76% to $1.5 million in 2024.
  • Its Depreciation & Amortization (CF) stands at $1.5 million for FY2024, versus $1.6 million for FY2023 and $1.7 million for FY2022.